Gossamer Bio (GOSS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on November 11. Analyst Joseph Schwartz from Leerink Partners reiterated a Buy rating on ...

In a report released today, Andreas Argyrides from Oppenheimer maintained a Buy rating on Gossamer Bio (GOSS – Research Report), with a price target of $9.00. The company’s shares closed yesterday at ...

As of the latest trading close, GOSS, a Healthcare sector stock, is trading -44.61% below its 52-week high but remains 89.62% above its 52-week low. The Average True Range (ATR) (14 days) of 0.06 ...

Gossamer Bio (GOSS) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.21 per share a year ago. These figures are ...

Gossamer Bio, Inc. ( NASDAQ:GOSS) shareholders will have a reason to smile today, with the analysts making substantial upgrades to next year's statutory forecasts. The consensus estimated revenue ...

Stephan Goss is president and CEO of Zeeto, a rapidly growing innovator of ad technology. Since he started Zeeto in 2010 at the age of 22 the company has grown from two employees to more than 60.

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and ...

Why restaurant etiquette matters In my many years working as a restaurant server, there was one rude restaurant habit that ...

The Sullivan Goss 40th Anniversary Show is on view through December 30. For longtime followers and friends of the gallery, it ...

Plus, a look into America’s Best Companies, how your personal brand can supercharge your career and a New York City bill that ...